Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 4:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lymph Node Biopsy Clear all
Active, not recruiting Phase 2 Interventional

Axillary Reverse Mapping

NCT00572481
View directory record Official record
Conditions
Cancer of the Breast
Interventions
Axillary Reverse Mapping
Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 27, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca

NCT01530997
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
Interventions
Intensity Modulated Radiotherapy (IMRT), Cisplatin, Limited surgical evaluation
Radiation · Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
5
States / cities
Colorado Springs, Colorado • Gainesville, Florida • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Sep 27, 2026, 4:53 AM EDT
Active, not recruiting Not applicable Interventional

Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer

NCT02515110
View directory record Official record
Conditions
Breast Cancer, Node-positive Breast Cancer, Breast Adenocarcinoma, Invasive Breast Carcinoma, Lobular Breast Carcinoma In Situ
Interventions
External Beam Radiation Therapy
Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
40 Years and older · Female only
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
2
States / cities
Richmond, Virginia • South Hill, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 27, 2026, 4:53 AM EDT
Terminated Early Phase 1 Interventional

Intratumoral Microdosing of Motolimod in HNSCC

NCT04272333
View directory record Official record
Conditions
HNSCC
Interventions
Motolimod, Nivolumab, Motolimod + Nivolumab
Drug · Biological · Combination Product
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
San Francisco, California • Chicago, Illinois • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 27, 2026, 4:53 AM EDT
Recruiting Not applicable Interventional

Magseed Enabled Long-Term Localization of Axillary Lymph Nodes

NCT03796559
View directory record Official record
Conditions
Breast Cancer, Axillary Lymph Nodes
Interventions
Magseed Marker
Device
Lead sponsor
Endomagnetics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 27, 2026, 4:53 AM EDT
Completed Early Phase 1 Interventional

PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC

NCT06062602
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
TAK-676, Carboplatin, 5-FU, Paclitaxel, TAK-676 + Carboplatin, Carboplatin + Paclitaxel, Carboplatin + 5-FU, TAK-676 + Carboplatin + 5-FU, TAK-676 + Carboplatin + Paclitaxel
Drug · Combination Product
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Shreveport, Louisiana • The Bronx, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Sep 27, 2026, 4:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

NCT07288112
View directory record Official record
Conditions
Refractory Melanoma
Interventions
DOC1021, Tumor resection, pIFN (peginterferon alfa-2a)
Biological · Procedure · Drug
Lead sponsor
Diakonos Oncology Corporation
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
8
States / cities
Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 27, 2026, 4:53 AM EDT
Completed Not applicable Interventional Results available

Pilot Study of Navigational Bronchoscopy and Transthoracic Needle Biopsy

NCT02109458
View directory record Official record
Conditions
Peripheral Pulmonary Nodules
Interventions
Navigation guided bronchoscopy
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 23, 2017 · Synced Sep 27, 2026, 4:53 AM EDT
Recruiting Phase 1 Interventional

A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer

NCT05412225
View directory record Official record
Conditions
Breast Cancer, Invasive Breast Cancer
Interventions
Pre-neoadjuvant radiotherapy (NART) biopsy, Neoadjuvant radiotherapy, Unilateral total mastectomy with axillary lymph node dissection
Diagnostic Test · Radiation · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 27, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

Lymph Node Mapping in Finding Metastatic Disease in Patients With Sebaceous Gland Cancer of the Eyelid

NCT00832429
View directory record Official record
Conditions
Eyelid Sebaceous Gland Carcinoma
Interventions
Lymph Node Mapping, Sentinel Lymph Node Biopsy, Technetium Tc-99m Sulfur Colloid
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Sep 27, 2026, 4:53 AM EDT
Completed Not applicable Interventional Results available

Comparison of Use of Indocyanine Green and 99mTc-labeled Radiotracer for Axillary Lymphatic Mapping in Patients With Breast Cancer

NCT02419807
View directory record Official record
Conditions
Stage I Breast Cancer, Stage II Breast Cancer
Interventions
Indocyanine Green Solution, Technetium Tc-99m Sulfur Colloid, Lymphoscintigraphy, Axillary Lymph Node Biopsy
Drug · Radiation · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Sep 27, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors

NCT00423865
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cisplatin, everolimus, gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2015 · Synced Sep 27, 2026, 4:53 AM EDT
Active, not recruiting Phase 2 Interventional

Swallowing Outcomes and Circulating Tumor DNA in Patients With HPV Related Oropharyngeal Cancer Treated With Transoral Surgery and Reduced Intensity Adjuvant Therapy

NCT04920344
View directory record Official record
Conditions
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Human Papillomavirus-Positive Squamous Cell Carcinoma
Interventions
Transoral Surgery, External Beam Radiation Therapy, Cisplatin, Incisional Tumor Biopsy, Circulating tumor deoxyribonucleic acid (ctDNA) levels assessment, MD Anderson Dysphagia Index, University of Washington Quality of Life Questionnaire, Euro-QOL 5 dimension scale questionnaire, Modified barium swallow (MBS) evaluation with aspiration-penetration scale
Procedure · Radiation · Drug + 2 more
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
New Brunswick, New Jersey • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 27, 2026, 4:53 AM EDT
Recruiting Phase 2 Interventional

A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information

NCT07621614
View directory record Official record
Conditions
Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Cutaneous Melanocytic Neoplasm, Cutaneous Melanoma, Cutaneous Spitz Melanocytoma, Cutaneous Spitz Melanoma
Interventions
Biospecimen Collection, Chest Radiography, Computed Tomography, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Patient Observation, Positron Emission Tomography, Re-Excision, Sentinel Lymph Node Biopsy, Ultrasound Imaging, Wide Local Excision
Procedure · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 25 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
13
States / cities
Oakland, California • Wilmington, Delaware • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 27, 2026, 4:53 AM EDT
Terminated No phase listed Observational Results available

A Non-Randomized Study to Evaluate Leg Lymphatic Drainage Associated With Surgical Intervention for Vulvar Cancer

NCT01321697
View directory record Official record
Conditions
Vulvar Cancer
Interventions
Routine Leg edema and groin dissection
Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2013 · Synced Sep 27, 2026, 4:53 AM EDT
Terminated Not applicable Interventional Results available

Arm Circumference Measurement With or Without Bioimpedance Spectroscopy in Finding Lymphedema Early in Patients With Stage I-III Breast Cancer

NCT03648983
View directory record Official record
Conditions
Lymphedema, Breast Cancer
Interventions
arm circumference measurement, Bioimpedance spectroscopy
Procedure · Device
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2018 · Synced Sep 27, 2026, 4:53 AM EDT
Enrolling by invitation Phase 2 Interventional

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for Gastric Cancer at High Risk of Peritoneal Recurrence

NCT07139951
View directory record Official record
Conditions
Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Hyperthermic Intraperitoneal Chemotherapy, Laparoscopy, Lymphadenectomy, Magnetic Resonance Imaging, Paclitaxel, Positron Emission Tomography, Surgical Procedure
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 27, 2026, 4:53 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Safety and Efficacy of OTL78 (Zopocianine)

NCT07725523
View directory record Official record
Conditions
Prostate Cancer Surgery, Prostate Cancer Metastatic Disease
Interventions
0.06mg/kg ZOPOCIANINE given 1-7 days prior to surgery
Drug
Lead sponsor
Clinton Bahler
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 27, 2026, 4:53 AM EDT
Completed Phase 2 Interventional

Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection

NCT06849544
View directory record Official record
Conditions
Prostate Cancer Surgery, Prostate Cancer Metastatic Disease
Interventions
0.03mg/kg ZOPOCIANINE given day of surgery, 0.06mg/kg ZOPOCIANINE given day of surgery, 0.03mg/kg ZOPOCIANINE given day prior to surgery, 0.06mg/kg ZOPOCIANINE given days prior to surgery
Drug
Lead sponsor
Clinton Bahler
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 27, 2026, 4:53 AM EDT
Recruiting Phase 2 Interventional

Lerapolturev (PVSRIPO) in GBM

NCT06177964
View directory record Official record
Conditions
Recurrent Supratentorial Glioblastoma
Interventions
Lerapolturev, Lomustine Pill
Drug
Lead sponsor
Darell Bigner
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 27, 2026, 4:53 AM EDT
Completed No phase listed Observational

PASSION - P Trial: Ph Adjusted Sulfur-Colloid, Sentinel Initiative ON Pain Trial

NCT00940199
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 14, 2009 · Synced Sep 27, 2026, 4:53 AM EDT
Completed Not applicable Interventional

Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

NCT01868451
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Brentuximab vedotin (SGN-35), Doxorubicin HCL, Vinblastine Sulfate, Dacarbazine, Involved-Site Radiation Therapy (ISRT), Interim PET, consolidation volume RT (CVRT)
Drug · Radiation · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
10
States / cities
Duarte, California • Stanford, California • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 27, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma

NCT03427476
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
CTT1057
Drug
Lead sponsor
Cancer Targeted Technology
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2019 · Synced Sep 27, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

Adoptive Transfer of Haploidentical NK Cells and N-803

NCT03899480
View directory record Official record
Conditions
Hiv, HIV Infections, Immune Deficiency
Interventions
Haploidentical Natural Killer (NK) Cells
Biological
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Sep 27, 2026, 4:53 AM EDT